GW-405,833 (L-768,242) is a drug that acts as a potent and selective partial agonist for the cannabinoid receptor subtype CB<sub>2</sub>, with an EC<sub>50</sub> of 0.65 nM and selectivity of around 1200x for CB<sub>2</sub> over CB<sub>1</sub> receptors. Animal studies have shown it to possess antiinflammatory and anti-hyperalgesic effects at low doses, followed by ataxia and analgesic effects when the dose is increased. Selective CB<sub>2</sub> agonist drugs such as GW-405,833 are hoped to be particularly useful in the treatment of allodynia and neuropathic pain for which current treatment options are often inadequate.